Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Brief Summary: This randomized, blinded, parallel arm study evaluated the efficacy and safety of tocilizumab (RoActemra/Actemra) versus adalimumab as monotherapy in patients with rheumatoid arthritis who are intolerant of methotrexate or where continued treatment with methotrexate was considered inappropriate. Patients were randomized to receive either tocilizumab 8 mg/kg intravenously (iv) every 4 weeks plus placebo subcutaneously (sc) every 2 weeks, or adalimumab 40 mg sc every 2 weeks plus placebo iv every 4 weeks. Treatment was anticipated to last 24 weeks. With regard to the blind, the study nurse was unblinded due to the nature of the treatment administration, but the investigator and the patient remained blinded.


Options:
A: Arm Label: methotrexate + adalimumab; Type: EXPERIMENTAL; Interventions: Drug: Adalimumab | Arm Label: methotrexate + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): methotrexate + adalimumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): methotrexate + placebo
B: Arm Label: Tocilizumab 8 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Tocilizumab, Drug: Placebo to adalimumab | Arm Label: Adalimumab 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab, Drug: Placebo to tocilizumab | Intervention Type: DRUG; Name: Tocilizumab; Assigned to Arm(s): Tocilizumab 8 mg/kg | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Adalimumab 40 mg | Intervention Type: DRUG; Name: Placebo to tocilizumab; Assigned to Arm(s): Adalimumab 40 mg | Intervention Type: DRUG; Name: Placebo to adalimumab; Assigned to Arm(s): Tocilizumab 8 mg/kg
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: MLTA3698A, Drug: leflunomide, Drug: methotrexate | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: adalimumab, Drug: leflunomide, Drug: methotrexate, Drug: placebo | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: leflunomide, Drug: methotrexate, Drug: placebo | Intervention Type: DRUG; Name: MLTA3698A; Assigned to Arm(s): A | Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): B | Intervention Type: DRUG; Name: leflunomide; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B, C
D: Arm Label: Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab, Drug: Methotrexate placebo | Arm Label: Adalimumab + methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab, Drug: Methotrexate | Arm Label: Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Biological: Adalimumab placebo | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab, Adalimumab + methotrexate | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Adalimumab + methotrexate, Methotrexate | Intervention Type: BIOLOGICAL; Name: Adalimumab placebo; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Methotrexate placebo; Assigned to Arm(s): Adalimumab

Answer: B